Merck Serono drops tecemotide
This article was originally published in Scrip
Executive Summary
Merck Serono has finally called it a day on the development of the MUC-1-based cancer vaccine tecemotide (formerly Stimuvax) in Stage III non-small cell lung cancer (NSCLC). Shares in the originator company,Oncothyreon dropped by nearly 6% on the news.